A B S T R A C T Fibrinogen survival and turnover were examined in 15 adult-onset diabetic patients. 25I-labeled fibrinogen was prepared from each patient during the period of poor carbohydrate control, or hyperglycemic period, and fibrinogen survival determined. Improved control was established in each patient and during this euglycemic period, fibrinogen survival was determined simultaneously with 1251-fibrinogen saved from the hyperglycemic period and 131I-labeled fibrinogen prepared from the patient during the euglycemic period. The results confirm reduced fibrinogen survival in hyperglycemic diabetic patients and demonstrate reversal of the fibrinogen abnormality when euglycemia is achieved. The results of the double-label experiments in the euglycemic period suggest that the fibrinogen molecule is not altered functionally and that an abnormal plasma or vascular environment is a more likely basis for reduced fibrinogen survival during hyperglycemia. Electrophoretic and chromatographic experiments demonstrated no gross chemical differences between the fibrinogens prepared from the hyperglycemic and euglycemic periods and normal fibrinogen. Fibrinogen survival gave a better correlation with serial glucose measurements than with correction of hemoglobin AIC levels indicating that the reduced fibrinogen survival noted in diabetics is a rapidly reversible phenomenon.
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During the hyperglycemic period, pharmacological intervention with aspirin and dipyrimadole was attempted to examine the role of platelets in reduced fibrinogen survival. No significant change in fibrinogen survival was observed. Heparin infusion during hyperglycemia normalized the fibrinogen kinetics of hyperglycemic diabetic patients, suggesting that reduced fibrinogen survival during hyperglycemia is secondary to an effect on thrombin or one of its antagonists.
INTRODUCTION
The major controversies in diabetes mellitus center around the relationship of glycemia or carbohydrate "control" to the numerous sequelae of the disease. It has been difficult to address this relationship because of the problems attendant in the definition of carbohydrate control. It is certainly possible to hospitalize patients and measure serial blood glucose as a means of characterizing short-term control. In addition, it is now possible to define control over periods of weeks to months through the use of minor fast hemoglobins, especially hemoglobin A,,. This glycohemoglobin (the 1-N-valyl-l-deoxy-fructose adduct of hemoglobin A) results from a postsynthetic modification of normal hemoglobin A and provides an accurate assessment of the mean blood glucose over the previous [3] [4] wk in individuals who are not suffering from hemolytic disease (1) . Several sequelae have now been shown to be reversible when strict definitions of control are applied. These "reversible sequelae" include disorders of erythrocyte survival, leukocyte function, platelet function, and hyperlipidemia (2, 3) .
Of the numerous secondary sequelae of diabetes, vascular disease now accounts for the major morbidity and mortality resulting from the diabetic state. The etiology of the increased risk of vascular disease in patients with diabetes mellitus is not clear. Most studies have focused on lipid abnormalities as the primary concomitant or causative factor predisposing the diabetic to vascular lesions. Recent studies suggest that abnormalities ofthe hemostatic system may also be involved in the initiation or propagation of vascular lesions (4).
Fibrinogen survival has been noted to be decreased in patients with diabetes (5). The present study was designed to determine whether the decreased survival of fibrinogen in patients with diabetes mellitus was reversible. With various measures of diabetic control, the time-course of the reversibility was assessed. In addition the studies were designed to assess whether the abnormalities in fibrinogen kinetics were the result of a postsynthetic modification of a normal fibrinogen molecule analogous to hemoglobin A1, production or the consequence of a normal molecule circulating in an abnormal environment. Finally, because the latter proved to be true, an attempt was made to pharmacologically correct the decreased fibrinogen survival seen in diabetics through the use of heparin infusions and aspirin and dipyrimadole administration.
METHODS
Patients. 15 patients with hyperglycemia and adult-onset, nonketotic diabetes mellitus of varying durations were admitted to The Rockefeller University Clinical Research Center. The patients had various complications including neuropathy, vascular disease, retinopathy, and(or) nephropathy as summarized in Table I . Diabetic neuropathy was identified by physical examination and nerve conduction studies. Vascular disease was evaluated by clinical findings as well as electrocardiographic criteria. Retinopathy was documented by fluorescein angiography and nephropathy by creatinine clearance. Patients with severe renal insufficiency as defined in Table I were excluded from the study.
Each patient was determined to be hyperglycemic by fasting blood glucose, urine sugars, glucose brackets, and hemoglobin A,, determinations. The "glucose brackets" is the sum of blood glucose values drawn before and 1 h after each meal for 1 d. This value represents the patient's ability to metabolize dietary challenges and has been shown to correlate well with 24-h integrated glucose concentrations (6). The blood glucose was brought under control by insulin or oral hypoglycemic therapy (chlorpropamide, Pfizer Laboratories Div., Pfizer Inc., New York), and dietary regulation (American Diabetes Association, 40-45% fat diet). Glycemia was also monitored by urine sugars, glucose brackets, and hemoglobin A,,.
To examine the possible mechanisms behind reduced fibrinogen survival the following protocol was adapted. In the hyperglycemic period, fibrinogen survival was studied with the patient's fibrinogen labeled with 1251. After the achievement of optimum blood glucose levels (euglycemic period), fibrinogen survival was determined simultaneously for 1311_ labeled fibrinogen purified from the patient during the euglycemic period and 1251-labeled fibrinogen saved from the hyperglycemic period.
Fibrinogen survival studies. Fibrinogen survival was determined with radioiodinated autologous fibrinogen labeled by the method of Takeda (7). This technique involved (11, 12) . Urine sugar was measured semiquantitatively (on a scale of from 0 to 4+) four times daily by standard methods (Clinitest, Ames Co., Elkhart, Ind.).
Hemoglobin A,, vas determined weekly on samples collected in EDTA by the column chromatographic method of Trivelli et al. (13) or by radioimmunoassay (14) .
Electrophoretic and chromatographic studies. DEAEcellulose (DE52, Whatman Ltd., Maidstone, Kent, England) chromatography was performed at 4°C wvith a continuous Tris-phosphate gradient (15) . Sephadex G-200 (Pharmacia Fine Chemicals, Piscataway, N. J.) column chromatography was performed at room temperature with a 0.2 M NaCl: 0.02 M Tris buffer (1:5) pH 8.0 (16) . For these experiments tracer amounts of 1251-labeled fibrinogen isolated during the hyperglycemic period and 131I-labeled fibrinogen samples isolated during the euglycemic period were mixed with 10-15 mg of unlabeled fibrinogen purified in the same manner from a nondiabetic individual and dialyzed extensively against starting buffer. Samples from these columns were counted in a twochannel gamma counter (Packard Instrument Co. Inc., Downers Grove, Ill.) and absorbance at 280 nm measured.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed on 8% gels with fibrinogen samples purified from the hyperglycemic and euglycemic periods, along with fibrinogen purified from a normal individual and commercially supplied human fibrinogen (Fraction 1, Sigma Chemical Co., St. Louis, Mo.) (17) . Gels were stained with Coomassie brilliant blue. The concentration of fibrinogen in purified samples for chromatography and electrophoresis was determined spectrophotometrically at 280 nm with an (A'z) of 13.9 (18) .
Statistics. Where applicable, values are expressed as the +1 SD. The difference between means was assessed by the Student's t test for paired data (19) . Differences were termed significant if the t value exceeded the 5% level.
RESULTS
Determinations of fibrinogen survival and turnover were performed in 15 patients during hyperglycemic and euglycemic periods. The interval between the end of the hyperglycemic period studies and the beginning of the euglycemic period varied between 1 and 9 wk (mean, 2.5 wk). This interval was dependent upon the time required to achieve euglycemia as evidenced by absence of urine sugar and optimum glucose brackets. Table II documents glucose brackets, fibrinogen survival and turnover studies, and coagulation studies during the various periods of the study. Carbohydrate control, (as evidenced by glucose brackets) was significantly improved in all patients from a mean hyperglycemic value of 1514 I 490 mg/100 ml to a mean euglycemic value of 710 1 138 mg/100 ml (P < 0.001).
Hemoglobin A., levels also showed a mean decrease of 1.7% of total hemoglobin from hyperglycemic to euglycemic periods. This decrease was not statistically significant, but the interval between studies was not sufficient for this measurement to reach a stable plateau during the control phase. Serum cholesterol (not shown) showed no significant change from hyperglycemic (213±40 mg/100 ml) to euglycemic (187±22 mg/lO0 ml) periods. Fasting serum triglycerides (not shown) also showed no significant change from during the two periods of the study (135±55 mg/100 ml to 124+42 mg/100 ml).
Prothrombin time, activated partial thromboplastin time, and thrombin time were in the normal range and did not change significantly from the hyperglycemic to euglycemic periods.
Plasma fibrinogen concentrations were elevated above normal range in 9 of the 15 patients studied. (20) . Fibrinogen survival in our patients was well below this normal level and increased significantly from a mean value of 3.45±0.57 d dturing hyperglycemia to a mean control value of 5.07±0.70 d (P < 0.001) during the euglycemic period. Moreover, when studied in the euglycemic period, the survival of fibrinogen saved from the hyperglycemic period and fibrinogen prepared in the euglycemic period were virtually the same. Fig. 1 shows the fibrinogen survival curves obtained from one patient (patient 5) and illustrates the identical fibrinogen survival for the two samples in the euglycemic period. This result implies that an abnormal plasma environment rather than an abnormal fibrinogen molecule accounts for the reduced fibrinogen survival in "uncontrolled" diabetes. If an abnormal fibrinogen molecule modified via glycosylation was the cause for the observed decrease in survival during hyperglycemia one would expect divergent curves in the euglycemic phase with the fibrinogen molecule isolated during the hyperglycemic period disappearing at a more rapid rate than the sample isolated during the euglycemic period.
Reduced Fibrinogen Suirvival Reversible in Diabetes Mellitus
Fibrinogen turnover was reduced in all patients studied during hyperglycemia by an average of 34.4%. The mean turnover value of 1.17±0.46 mg/ml per d improved to a mean value of 0.71±0. 23 Days FIGURE 1 Fibrinogen survival curves from patient 5. In the hyperglycemic period fibrinogen survival was studied with autologous fibrinogen labeled with 125I. After carbohydrate control, fibrinogen survival was studied simultaneously with 13I-labeled fibrinogen purified during euglycemic period and 1251-labeled fibrinogen saved from the hyperglycemic period.
Reduced Fibrinogen Survival Reversible in Diabetes Mellitus from the hyperglycemic period and 131I-labeled sample from the euglycemic period coelute with the unlabeled fibrinogen from a nondiabetic subject. This result suggests that all these fibrinogen samples have similar charge. Similarly gel filtration chromatography showed no differences in molecular weight between diabetic hyperglycemic sample, euglycemic sample, and nondiabetic subject samples. Sodium dodecyl sulfatepolyacrylamide gel electrophoresis showed comigration of the major bands of samples isolated during periods of hyperglycemia and euglycemia from diabetic patients, nondiabetic fibrinogen purified in a similar manner and commercially available fibrinogen. Pharmacological intervention. Four patients were placed on continuous heparin infusions and fibrinogen survival was repeated while the blood glucose remained at hyperglycemic level. Table III shows the results of these studies along with the mean partial thromboplastin time as monitored during the heparin infusion. Patients 7 and 15 had a mean partial thromboplastin time barely in the therapeutic range and had significant, although incomplete, normalization of fibrinogen survival from the hyperglycemic to the hyperglycemic(heparin) period. Patients 9 and 11 were maintained at the upper limits of the therapeutic range and each had normal fibrinogen survivals during the hyperglycemic(heparin) and euglycemic periods of the study.
The in vitro hyperaggregation of platelets in diabetes mellitus has been noted to be reversible when the blood glucose is normalized (2). It was conceivable that decreased fibrinogen survival during hyperglycemia could be a result of increased intravascular coagulation initiated or propagated by hyperaggregating platelets. Four patients were placed on aspirin and dipyridamole immediately after the initial study offibrinogen survival and restudied during hyperglycemia with 1251-labeled sample. Inhibition of in vitro platelet aggregation was verified by complete elimination of the secondary wave of aggregation in response to 70 ,uM epinephrine. An insignificant improvement in fibrinogen survival was seen during the hyperglycemic(aspirin and dipyrimadole) period, whereas a significant improvement occurred when the patients were brought under carbohydrate control (Table IV) .
DISCUSSION
Vascular complications including atherosclerosis and microvascular disease now account for the major morbidity and mortality associated with diabetes mellitus (21) . Recent attention to the interaction between the vascular system and coagulation factors implicates involvement of certain aspects of coagulation in the genesis of vascular lesions. Several observations suggest the existence of a hypercoagulable state in patients with diabetes, particularly in those patients with vascular disease. These observations include increased levels of fibrinogen and Factors V and VIII, and shortened plasma cephalin time (22, 23) . Deposits of fibrin have been demonstrated in diabetic microvascular lesions by immunofluorescence (24) . Thus, there appears to be evidence for a fibrinocoagulopathy concomitant with the development of diabetic vascular disease.
The present study confirms the existence of elevated Blood and tissue proteins have been shown to be altered in diabetes by nonenzymatic glycosylation reactions thus altering their function or turnover (26, 27) . In the case of hemoglobin, the conversion of hemoglobin A to hemoglobin Air proceeds by the nonenzymatic addition of glycosyl residues and the rate of adduct formation both in vitro and in vivo and is related to the ambient concentration of glucose (28 Heparin is a potent anticoagulant that inhibits the action of thrombin as well as Factors XIa, IXa, Xa, and plasmin (32) . Inhibition of these factors is believed to proceed by the potentiation of the protease inhibitor antithrombin III. Correction of reduced fibrinogen survival during hyperglycemia by heparin suggests involvement of one of these factors or antithrombin III in the fibrinogcoagulopathy of diabetes. It is generally accepted that the improvement of pathologically decreased fibrinogen survival by heparin is caused by interference with the action of thrombin on fibrinogen to form fibrin monomer (20) . Our results showing correction of decreased fibrinogen survival by heparin infusion support the concept that a hypercoagulable state exists in uncontrolled diabetes and implicates the action of thrombin or its antagonists.
The interval between the hyperglycemic study and euglycemic study varied between 1 and 9 wk with a mean of 2.5 wk. The abnormality is rapidly reversible because there is a higher correlation between fibrinogen survival and glucose brackets (a measure of short term control) than between fibrinogen survival and hemoglobin A1, levels (Fig. 2) causative of, concomitant with, or a result of vascular disease. However, it seems unlikely that the reduced fibrinogen survival of hyperglycemia would be rapidly reversible during euglycemia ifit were secondary to the presence of either macro-or microvascular disease. It should be emphasized that the present study was carried out with adult-onset diabetics all of whom presumably have some degree of vascular disease. Furthermore, studies involving juvenile-onset diabetes of recent onset and presumably without vascular disease are warranted to dissect the cause and effect relationship between coagulopathy and vascular disease in diabetes. If 
